Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 6 (1), 38-51

Histone Deacetylase Inhibitors and the Promise of Epigenetic (And More) Treatments for Cancer

Affiliations
Review

Histone Deacetylase Inhibitors and the Promise of Epigenetic (And More) Treatments for Cancer

Saverio Minucci et al. Nat Rev Cancer.

Abstract

Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clinical trials. A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved. However, several basic aspects are not yet fully understood. Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clinical protocols.

Similar articles

See all similar articles

Cited by 692 PubMed Central articles

See all "Cited by" articles

Substances

LinkOut - more resources

Feedback